
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Synaptogenix Inc (SNPX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SNPX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $14
1 Year Target Price $14
0 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 108.8% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.40M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta 1.3 | 52 Weeks Range 1.84 - 7.85 | Updated Date 06/30/2025 |
52 Weeks Range 1.84 - 7.85 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.46 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -17.29% | Return on Equity (TTM) -83.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5152977 | Price to Sales(TTM) - |
Enterprise Value -5152977 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.28 | Shares Outstanding 1389820 | Shares Floating 1380698 |
Shares Outstanding 1389820 | Shares Floating 1380698 | ||
Percent Insiders 1.9 | Percent Institutions 3.76 |
Analyst Ratings
Rating 1 | Target Price 14 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Synaptogenix Inc

Company Overview
History and Background
Synaptogenix Inc., formerly known as Transition Therapeutics Inc., is a biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases. The company was founded in 1998 and has undergone name changes and strategic shifts, including a focus on Alzheimer's disease.
Core Business Areas
- Drug Development: Focuses on the development and commercialization of Bryostatin-1 for the treatment of Alzheimer's disease and other neurodegenerative conditions.
Leadership and Structure
The leadership team includes experienced pharmaceutical executives and scientists. The company operates with a lean organizational structure, focusing on research and development and clinical trials.
Top Products and Market Share
Key Offerings
- Bryostatin-1: Bryostatin-1 is Synaptogenix's lead drug candidate for Alzheimer's disease. Currently in clinical trials. No current market share or revenue as it's not yet approved. Key competitors: Eli Lilly (Donanemab), Biogen (Aduhelm), Eisai (Leqembi).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investment in research and development for neurodegenerative diseases like Alzheimer's. Regulatory hurdles and clinical trial success are critical factors.
Positioning
Synaptogenix is positioned as a company developing a novel therapy for Alzheimer's disease, targeting a different mechanism of action than existing or near-term competitors. They are a smaller player compared to established pharmaceutical giants.
Total Addressable Market (TAM)
The Alzheimer's disease market is estimated to be worth billions of dollars annually. Synaptogenix aims to capture a portion of this market with Bryostatin-1, focusing on patients who may not respond to existing treatments. The TAM is estimated in the hundreds of Billions. They are pursuing a fraction of the total market with a novel treatment.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach with Bryostatin-1
- Experienced leadership team
- Focus on a large and underserved market
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
- Dependence on the success of Bryostatin-1
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
Threats
- Clinical trial failures
- Competition from established Alzheimer's treatments
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- ESAI
Competitive Landscape
Synaptogenix faces intense competition from larger pharmaceutical companies with established Alzheimer's treatments. Synaptogenix is currently developing Bryostatin-1, which is in Phase II of its clinical trials and has not yet had its market share analyzed. The listed competitors, LLY, BIIB, and ESAI have already developed treatments for Alzheimer's with proven market shares.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial progress and funding rounds.
Future Projections: Future growth depends on the successful development and commercialization of Bryostatin-1. Analyst estimates are speculative and based on clinical trial outcomes.
Recent Initiatives: Focus on advancing Bryostatin-1 through clinical trials and seeking partnerships.
Summary
Synaptogenix is a high-risk, high-reward biopharmaceutical company focused on developing Bryostatin-1 for Alzheimer's disease. Its success hinges on positive clinical trial outcomes and securing partnerships. While the company operates in a large market, it faces strong competition from established players and requires significant funding to continue its research and development efforts. Potential investors should carefully consider the risks and uncertainties associated with drug development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be entirely accurate or complete. Investments in biopharmaceutical companies are speculative and involve significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Synaptogenix Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-12-08 | CEO & Director Dr. Alan J. Tuchman M.D., MBA(FAAN) | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.synaptogen.com |
Full time employees 4 | Website https://www.synaptogen.com |
Synaptogenix, Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. The company was incorporated in 2012 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.